Serum Interleukin-33 level in Saudi children with inflammatory bowel disease

International Journal of Clinical and Experimental Pathology

Volumn 8, Issue 12, 2015, Pages 16000-16006

  Saadah, Omar I ^a   Al Harthi, Sameer E ^a   Al Mughales, Jamil A ^a   Bin Taleb, Yagoub Y ^a   Baeshen, Raed S ^b  

^a KING ABDULAZIZ UNIVERSITY   (Saudi Arabia)

^b King Abdulaziz University   (Saudi Arabia)

Author keywords

Children; Crohn's disease (CD); IL 33; Saudi Arabia; Ulcerative colitis (UC)

Indexed keywords

AUTACOID; BIOLOGICAL MARKER; BIOLOGICAL PRODUCT; C REACTIVE PROTEIN; IL33 PROTEIN, HUMAN; INTERLEUKIN 33;

ADOLESCENT; AGE; BLOOD; CASE CONTROL STUDY; CHILD; COLITIS, ULCERATIVE; CROHN DISEASE; CROSS-SECTIONAL STUDY; DIFFERENTIAL DIAGNOSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; IMMUNOLOGY; MALE; PHOTOMETRY; PREDICTIVE VALUE; PROGNOSIS; PROSPECTIVE STUDY; SAUDI ARABIA; SEVERITY OF ILLNESS INDEX; UPREGULATION;

ADOLESCENT; AGE FACTORS; BIOLOGICAL PRODUCTS; BIOMARKERS; C-REACTIVE PROTEIN; CASE-CONTROL STUDIES; CHILD; COLITIS, ULCERATIVE; CROHN DISEASE; CROSS-SECTIONAL STUDIES; DIAGNOSIS, DIFFERENTIAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; INFLAMMATION MEDIATORS; INTERLEUKIN-33; MALE; NEPHELOMETRY AND TURBIDIMETRY; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSPECTIVE STUDIES; SAUDI ARABIA; SEVERITY OF ILLNESS INDEX; UP-REGULATION;

EID: 84963782518     PISSN: None     EISSN: 19362625     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Söderholm JD, Olaison G, Peterson KH, Franzén LE, Lindmark T, Wirén M, Tagesson C, Sjödahl R. Augmented increase in tight junction permeability by luminal stimuli in the non-inflamed ileum of Crohn's disease. Gut 2002; 50: 307-13.
2. Gitter AH, Wullstein F, Fromm M, Schulzke JD. Epithelial barrier defects in ulcerative colitis: characterization and quantification by electrophysiological imaging. Gastroenterology 2001; 121: 1320-8.
3. Beltrán CJ, Núñez LE, Díaz-Jiménez D, Farfan N, Candia E, Heine C, López F, González MJ, Quera R, Hermoso MA. Characterization of the novel ST2/IL-33 system in patients with inflammatory bowel disease. Inflamm Bowel Dis 2010; 16: 1097-107.
4. Kobori A, Yagi Y, Imaeda H, Ban H, Bamba S, Tsujikawa T, Saito Y, Fujiyama Y, Andoh A. Interleukin-33 expression is specifically enhanced in inflamed mucosa of ulcerative colitis. J Gastroenterol 2010; 45: 999-1007.
5. Pastorelli L, Garg RR, Hoang SB, Spina L, Mattioli B, Scarpa M, Fiocchi C, Vecchi M, Pizarro TT. Epithelial-derived IL-33 and its receptor ST2 are dysregulated in ulcerative colitis and in experimental Th1/Th2 driven enteritis. Proc Natl Acad Sci U S A 2010; 107: 8017-22.
6. Seidelin JB, Bjerrum JT, Coskun M, Widjaya B, Vainer B, Nielsen OH. IL-33 is upregulated in colonocytes of ulcerative colitis. Immunol Lett 2010; 128: 80-5.
7. Schmitz J, Owyang A, Oldham E, Song Y, Murphy E, McClanahan TK, Zurawski G, MoshrefiM, Qin J, Li X, Gorman DM, Bazan JF, Kastelein RA. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity 2005; 23: 479-90.
8. Zhu J, Carver W. Effects of interleukin-33 on cardiac fibroblast gene expression and activity. Cytokine 2012; 58: 368-79.
9. Willems S, Hoefer I, Pasterkamp G. The role of the interleukin 1 receptor-like 1 (ST2) and Interleukin-33 pathway in cardiovascular disease and cardiovascular risk assessment. Minerva Med 2012; 103: 513-24.
10. Wang S, Ding L, Liu SS, Wang C, Leng RX, Chen GM, Fan YG, Pan HF, Ye DQ. IL-33: A Potential Therapeutic Target in Autoimmune Diseases. J Investig Med 2012; 60: 1151-6.
11. Liew FY. IL-33: a Janus cytokine. Ann Rheum Dis 2012; 71 Suppl 2: i101-4.
12. Xu D, Jiang HR, Li Y, Pushparaj PN, Kurowska-Stolarska M, Leung BP, Mu R, Tay HK, McKenzie AN, McInnes IB, Melendez AJ, Liew FY. IL-33 exacerbates autoantibody-induced arthritis. J Immunol 2010; 184: 2620-6.
13. Komai-Koma M, Gilchrist DS, McKenzie AN, Goodyear CS, Xu D, Liew FY. IL-33 activates B1 cells and exacerbates contact sensitivity. J Immunol 2011; 186: 2584-91.
14. Smith DE. The biological paths of IL-1 family members IL-18 and IL-33. J Leukoc Biol 2011; 89: 383-92.
15. Haraldsen G, Balogh J, Pollheimer J, Sponheim J, Küchler AM. Interleukin-33-cytokine of dual function or novel alarmin? Trends Immunol 2009; 30: 227-33.
16. Stolarski B, Kurowska-Stolarska M, Kewin P, Xu D, Liew FY. IL-33 exacerbates eosinophil-mediated airway inflammation. J Immunol 2010; 185: 3472-80.
17. Sattler S, Smits HH, Xu D, Huang FP. The Evolutionary Role of the IL-33/ST2 System in Host Immune Defense. Arch Immunol Ther Exp (Warsz) 2013; 61: 107-17.
18. Xie Q, Wang SC, Zhong J, Li J. Therapeutic potential of IL-33 in rheumatoid arthritis: A comment about the article by Talabot-Ayer D, et al., "Distinct serum and synovial fluid interleukin (IL)-33 levels in rheumatoid arthritis, psoriatic arthritis and osteoarthritis", Joint Bone Spine 2012;79:32-7. Joint Bone Spine 2012; 80: 116-7.
19. Yin H, Li XY, Liu T, Yuan BH, Zhang BB, Hu SL, Gu HB, Jin XB, Zhu JY. Adenovirus-mediated delivery of soluble ST2 attenuates ovalbumininduced allergic asthma in mice. Clin Exp Immunol 2012; 170: 1-9.
20. Kim YH, Park CS, Lim DH, Ahn SH, Son BK, Kim JH, Jang TY. Beneficial effect of anti-interleukin-33 on the murine model of allergic inflam mation of the lower airway. J Asthma 2012; 49: 738-43.
21. Komai-Koma M, Brombacher F, Pushparaj PN, Arendse B, McSharry C, Alexander J, Chaudhuri R, Thomson NC, McKenzie AN, McInnes I, Liew FY, Xu D. Interleukin-33 amplifies IgE synthesis and triggers mast cell degranulation via interleukin-4 in naive mice. Allergy 2012; 67: 1118-26.
22. Oboki K, Ohno T, Kajiwara N, Arae K, Morita H, Ishii A, Nambu A, Abe T, Kiyonari H, Matsumoto K, Sudo K, Okumura K, Saito H, Nakae S. IL-33 is a crucial amplifier of innate rather than acquired immunity. Proc Natl Acad Sci U S A 2010; 107: 18581-6.
23. Grob P, Doser K, Falk W, Obermeier F, Hofmann C. IL-33 attenuates development and perpetuation of chronic intestinal inflammation. Inflamm Bowel Dis 2012; 18: 1900-9.
24. IBD Working Group of the European Society for Paediatric Gastroenterology, Hepatology and Nutrition. Inflammatory bowel disease in children and adolescents: recommendations for diagnosis-the Porto criteria. J Pediatr Gastroenterol Nutr 2005; 41: 1-7.
25. North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition; Colitis Foundation of America, Bousvaros A, Antonioli DA, Colletti RB, Dubinsky MC, Glickman JN, Gold BD, Griffiths AM, Jevon GP, Higuchi LM, Hyams JS, Kirschner BS, Kugathasan S, Baldassano RN, Russo PA. Differentiating ulcerative colitis from Crohn disease in children and young adults: report of a working group of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition and the Crohn's and Colitis Foundation of America. J Pediatr Gastroenterol Nutr 2007; 44: 653-74.
26. Satsangi J, Silverberg MS, Vermeire S, Colombel JF. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut 2006; 55: 749-53.
27. Gasche C, Scholmerich J, Brynskov J, D'Haens G, Hanauer SB, Irvine EJ, Jewell DP, Rachmilewitz D, Sachar DB, Sandborn WJ, Sutherland LR. A simple classification of Crohn's disease: report of the Working Party for the World Congresses of Gastroenterology, Vienna 1998. Inflamm Bowel Dis 2000; 6: 8-15.
28. Rutgeerts P, Sandborn WJ, Feagan BG, Reinisch W, Olson A, Johanns J, Travers S, Rachmilewitz D, Hanauer SB, Lichtenstein GR, de Villiers WJ, Present D, Sands BE, Colombel JF. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005; 353: 2462-76.
29. Shepanski MA, Markowitz JE, Mamula P, Hurd LB, Baldassano RN. Is an abbreviated Pediatric Crohn's Disease Activity Index better than the original? J Pediatr Gastroenterol Nutr 2004; 39: 68-72.
30. Turner D, Otley AR, Mack D, Hyams J, de Bruijne J, Uusoue K, Walters TD, Zachos M, Mamula P, Beaton DE, Steinhart AH, Griffiths AM. Development, validation, and evaluation of a pediatric ulcerative colitis activity index: a prospective multicenter study. Gastroenterology 2007; 133: 423-32.
31. Ledue TB, Weiner DL, Sipe JD, Poulin SE, Collins MF, Rifai N. Analytical evaluation of particle-enhanced immunonephelometric assays for C-reactive protein, serum amyloid A and mannose-binding protein in human serum. Ann Clin Biochem 1998; 35: 745-53.
32. Pastorelli L, De Salvo C, Cominelli MA, Vecchi M, Pizarro TT. Novel cytokine signaling pathways in inflammatory bowel disease: insight into the dichotomous functions of IL-33 during chronic intestinal inflammation. Therap Adv Gastroenterol 2011; 4: 311-23.
33. Sponheim J, Pollheimer J, Olsen T, Balogh J, Hammarström C, Loos T, Kasprzycka M, Sørensen DR, Nilsen HR, Küchler AM, Vatn MH, Haraldsen G. Inflammatory bowel disease-associated interleukin-33 is preferentially expressed in ulceration-associated myofibroblasts. Am J Pathol 2010; 177: 2804-15.
34. Gunawardena CK, Zijlstra RT, Beltranena E. Characterization of the nutritional value of airclassified protein and starch fractions of field pea and zero-tannin faba bean in grower pigs. J Anim Sci 2010; 88: 660-70.
35. Bamias G, Martin C, Mishina M, Ross WG, Rivera-Nieves J, Marini M, Cominelli F. Proinflammatory effects of TH2 cytokines in a murine model of chronic small intestinal inflammation. Gastroenterology 2005; 128: 654-66.
36. Rivera-Nieves J, Bamias G, Vidrich A, Marini M, Pizarro TT, McDuffie MJ, Moskaluk CA, Cohn SM, Cominelli F. Emergence of perianal fistulizing disease in the SAMP1/YitFc mouse, a spontaneous model of chronic ileitis. Gastroenterology 2003; 124: 972-82.